Can­cer drug pro­gram lift

Townsville Bulletin - - STATE OF ORIGIN III -

SHARES in Aus­tralian biotech Prima Biomed have surged more than 40 per cent af­ter it re­ceived Euro­pean endorsement for the de­vel­op­ment pro­gram of a drug to treat breast can­cer.

Prima is plan­ning a Phase IIb clin­i­cal trial of its lead prod­uct, IMP321, on about 200 pa­tients with metastatic breast can­cer due in the later part of this year.

Prima said yesterday it had re­ceived pos­i­tive sci­en­tific ad­vice from the Lon­don- based Euro­pean Medicines Agency ( EMA) on the de­vel­op­ment path for IMP321. The EMA is re­spon­si­ble for the sci­en­tific eval­u­a­tion of medicines de­vel­oped by phar­ma­ceu­ti­cal com­pa­nies for use in the Euro­pean Union.

Sci­en­tific ad­vice is a pro­ce­dure of­fered by the EMA to phar­ma­ceu­ti­cal firms to clar­ify ques­tions aris­ing dur­ing the de­vel­op­ment of medic­i­nal prod­ucts.

Prima shares closed 2.6¢, or 44.07 per cent, higher at 8.5¢.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.